The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas.
Connor J KinslowSoumyajit RoyFabio M IwamotoPaul D BrownDavid M DeStephanoPeter D CanollSummer S QureshiMatthew GallitoMichael B SistiJeffrey N BruceDavid P HorowitzLisa A KachnicAlfred I NeugutJames B YuMinesh P MehtaSimon K ChengTony J C WangPublished in: Neuro-oncology (2024)
Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.